Flamel Technologies S.A. (ADR) (NASDAQ:FLML) just hit a fresh high moving above the psychologically-important $10 per share level for the first time. This mark is very close to the 52 week high for Flamel Technologies which has added more than 45% in the last 12 weeks, suggesting that decent momentum is present in FLML. We actually give FLML a Zacks Rank #4 (Sell) based on this information and think that the move higher for this company might be a bit overdone. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) shares after opening at $14.50 on last trade day and at the end of the day closed at $14.32. Company price to sales ratio in past twelve months was calculated as 15.45 and price to cash ratio as 39.12. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) showed a positive weekly performance of 34.84%.
After Horizon Pharma Inc (NASDAQ:HZNP) announced that it would acquire Vidara Therapeutics for $660M, Stifel thinks the deal will be 10% accretive in 2014 and 10%-20% accretive beyond that. The firm believes that Horizon’s deal activity is favorable overall as it increases product diversity and leverages the company’s promotional activities. Stifel keeps an $18 price target and Buy rating on the shares. Horizon Pharma Inc (NASDAQ:HZNP) shares advanced 3.21% in last trading session and ended the day on $17.35. HZNP return on equity ratio is recorded as -85.30% and its return on assets is -41.40%. Horizon Pharma Inc (NASDAQ:HZNP) yearly performance is 577.73%.
Neuralstem, Inc. (NYSEMKT:CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis were published in the peer-reviewed journal, “Annals of Neurology”. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits.Neuralstem, Inc. (NYSEMKT:CUR) shares moved down -8.03% in last trading session and was closed at $4.24, while trading in range of $4.11 – 4.79. Neuralstem, Inc. (NYSEMKT:CUR) year to date (YTD) performance is 45.70%.
Analysts at RBC Capital raised their price objective on shares of Prothena Corp (NASDAQ:PRTA) from $38.00 to $52.00 in a research report issued to clients and investors on Wednesday, AnalystRatings.Net reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 7.66% from the company’s current price. Prothena Corporation PLC (NASDAQ:PRTA) weekly performance is 16.98%. On last trading day company shares ended up $45.48. Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average (SMA50) is43. 78%.
Leave a Reply